Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9815358 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL155518 | 0.84 | MLYCD (0.58) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL29772431 | 0.84 | MLYCD (0.58) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL24998749 | 0.84 | MLYCD (0.58) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL9783640 | 0.84 | HDAC1 (0.60) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL6834922 | 0.83 | ALDH1A1 (0.56) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| Hydrochloric Acid SCHEMBL28544859 | 0.83 | MLYCD (0.56) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL7522945 | 0.83 | MLYCD (0.56) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| Hydrochloric Acid SCHEMBL7849680 | 0.83 | MLYCD (0.56) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL9815318 | 0.83 | LMNA (0.61) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354448-B2 | Use of (−)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of type 2 diabetes | METABOLEX, INC. (US) | 2013-01-15 | — | — | US | claimed |
| US-8329749-B2 | Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia | METABOLEX, INC. (US) | 2012-12-11 | — | — | US | claimed |
| US-8481597-B2 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia | METABOLEX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8354448-B2 | Use of (−)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of type 2 diabetes | METABOLEX, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8329749-B2 | Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia | METABOLEX, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-1343493-B1 | USE OF(-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES AND HYPERURICEMIA | METABOLEX INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120225940-A1 | Use of (-) (3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Insulin Resistance, Type 2 Diabetes, Hyperlipidemia and Hyperuricemia | DIATEX, INC. | 2012-09-06 | — | — | US | disclosed |
| EP-1614418-B1 | use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of hyperuricaemia | METABOLEX INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100093853-A1 | USE OF (-)(3-TRIHALOMETHYLPHENOXY)(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES AND HYPERLIPIDEMIA | METABOLEX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093855-A1 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA | METABOLEX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7576131-B2 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia | METABOLEX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-6613802-B1 | Composition containing (-) enantiomer of compound in enantiomeric excess of at least 80% relative to (+) enantiomer, which exhibits reduced inhibition of cytochrome P450 2C9 | METABOLEX, INC. | 2003-09-02 | — | — | US | disclosed |
| WO-2002044113-A9 | USE OF(-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA | METABOLEX INC (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2002044113-A2 | USE OF(-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA | METABOLEX, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-1183020-A2 | USE OF(-)(3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL)ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA | METABOLEX, INC. (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6262118-B1 | THERAPY OF TYPE 2 DIABETES IN A MAMMAL BY ADMINISTERING (-) 4-CHLOROPHENYL-(3-TRIFLUOROMETHYLPHENOXY)ACETIC ACID DERIVATIVE | METABOLEX, INC. | 2001-07-17 | — | — | US | disclosed |
| WO-2000074666-A2 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA | METABOLEX, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| EP-0767221-B1 | Near infrared ray absorbing compound having high durability and its use | MITSUI CHEMICALS INC (JP) | 2000-07-05 | — | — | EP | disclosed |
| US-5788914-A | Near infrared ray absorbing compound having high durability and its use | MITSUI CHEMICALS, INC. (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0767221-A1 | Near infrared ray absorbing compound having high durability and its use | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1997-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225940-A1 | Use of (-) (3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Insulin Resistance, Type 2 Diabetes, Hyperlipidemia and Hyperuricemia | HACL2, SLC5A2, HCAR2 | SMN1; SMN2 4344/4885LMNA 3555/4885ALDH1A1 217/4885 |
| US-20100093853-A1 | USE OF (-)(3-TRIHALOMETHYLPHENOXY)(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES AND HYPERLIPIDEMIA | GPR119, LIPC, HACL2 | SMN1; SMN2 4676/4885LMNA 3713/4885ALDH1A1 581/4885 |
| US-20100093855-A1 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA | HACL2, SLC5A2, HCAR2 | SMN1; SMN2 4344/4885LMNA 3555/4885ALDH1A1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.